Other news to note
Friday, December 13, 2013
Ico Therapeutics Inc., of Vancouver, British Columbia, said its oral amphotericin B is moving into in vitro testing with study partners in Montreal to examine the role of the formulation in targeting latent HIV reservoirs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.